share_log

HC Wainwright & Co. Maintains Buy on Gain Therapeutics, Lowers Price Target to $9

HC Wainwright & Co. Maintains Buy on Gain Therapeutics, Lowers Price Target to $9

HC Wainwright & Co.维持增益疗法的买入,将目标价下调至9美元
Benzinga ·  2023/12/04 06:47

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Gain Therapeutics (NASDAQ:GANX) with a Buy and lowers the price target from $10 to $9.

HC Wainwright & Co. 分析师Raghuram Selvaraju维持Gain Therapeutics(纳斯达克股票代码:GANX)的买入,并将目标股价从10美元下调至9美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发